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Objectives: To describe factors associated with survival in human
immunodeficiency virus (HIV)-infected subjects with non-small cell
lung cancer (NSCLC) and analyze toxicities induced by cytotoxic
chemotherapy and antiretroviral compounds.
Design: Retrospective analyses of HIV-infected subjects with NSCLC
enrolled in the Dat’Aids cohort. A toxicity substudy included subjects
treated by at least one cycle of cytotoxic chemotherapy.
Methods: Survival was analyzed using Cox models. In the toxicity
substudy, factors associated with grade 4 hematological toxicity of each
episode of combination of antiretroviral drugs and cytotoxic chemo-
therapy were analyzed using marginal logistic regression models.
Results: Fifty-two subjects were included in the study: 42 were
men, median age was 48 years, 98% were smokers, with a median
of 30 pack years, median CD4 was 300 cells/l, and median survival
time was 12 months. CD4 levels200 cells/l at NSCLC diagnosis
(hazard ratio [HR]  0.29, 95% confidence interval [CI] [0.10–
0.89]), performance status less than 2 (HR  0.32, 95% CI [0.15–
0.68]) and highly active antiretroviral therapy (HR  0.26, 95% CI
[0.09–0.74]) were significantly associated with increased survival in
the multivariable model. Forty subjects were included in the toxicity
substudy, and 14 among 68 different combinations were complicated
by a grade 4 hematological toxicity. Protease inhibitor use (odds ratio
5.22, 95% CI [1.07–25.38]) was significantly associated with grade 4
hematological toxicity in the multivariable analyses.
Conclusions: In HIV-infected patients, CD4 levels at NSCLC
diagnosis may be a predictive factor of survival. Use of highly active
antiretroviral therapy during NSCLC chemotherapy is warranted,
but protease inhibitors should be used with caution, as they may
enhance severe hematological toxicities.
Key Words: HIV, Antiretroviral therapy, HAART, NSCLC, Lung
cancer, CD4 lymphocytes, Chemotherapy, Toxicity, Interaction.
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Despite highly active antiretroviral therapy (HAART), theincidence of some non-acquired immunodeficiency syn-
drome (AIDS) cancers in human immunodeficiency virus
(HIV)-infected subjects is significantly increased compared
with non-HIV-infected subjects in resource-rich settings.1,2
Among these cancers, lung cancer is the primary cause of
mortality by non-AIDS cancers in the HIV-infected popula-
tion1,3–7 even after adjusting for age, sex,1,3,7 and smoking
history.5,8 HIV-related immunodeficiency may explain in part
the increased risk of lung cancer in the HIV-infected popu-
lation,2,5,8,9 although smoking remains the primary risk factor.
There are no specific recommendations for the manage-
ment of lung cancers in the HIV-infected population. In the
general population, patients with advanced non-small cell
lung cancer (NSCLC) are usually treated with a combination
of a platinum drug (cisplatin or carboplatin) and a third
generation nonplatinum drug (docetaxel, gemcitabine, irino-
tecan, paclitaxel, pemetrexed, or vinorelbine) resulting in a
slight increase in survival and relief of cancer-related symp-
toms.10 Strategies aiming to further improve survival of
patients with advanced NSCLC include the addition of tar-
geted drugs to cytotoxic chemotherapy, such as epidermal
growth factor receptor or antivascular endothelial growth
factor monoclonal antibodies,11,12 receptor protein kinase
inhibitors,13 and pursuing maintenance therapy with pem-
etrexed after first-line chemotherapy.14 The aim of antiretro-
*Infectious Diseases Department, CHRU Montpellier, Montpellier; †UMR
233, Institut de Recherche pour le De´veloppement, University of Mont-
pellier 1, Montpellier; ‡Thoracic Oncology Unit, CHRU Montpellier,
Montpellier; §Infectious Diseases Department, CHU Hoˆtel Dieu, Nantes;
Infectious Diseases Department, CHU Purpan, Toulouse; ¶Department
of Immuno-Hematology, CHU Sainte-Marguerite, Marseille; #Infectious
Diseases Department, CH Tourcoing, Tourcoing; **Infectious Diseases
Department, CHU Fort-de-France; and ††Infectious Diseases Depart-
ment, CHU Nice, Nice, France.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Alain Makinson, MD, Département des Mala-
dies Infectieuses, Hôpital Gui de Chauliac, CHRU Montpellier, 80
avenue Augustin Fliche, 34295 Montpellier Cedex 5, Montpellier,
France. E-mail: a-makinson@chu-montpellier
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0606-1022
Journal of Thoracic Oncology • Volume 6, Number 6, June 20111022
viral treatment is to provide durable virological, immunolog-
ical, and clinical benefits, while minimizing toxicities and
drug resistance. Two Nucleos(t)ide Reverse Transcriptase
(NRTI) (usually tenofovir or abacavir  emtricitabine or
lamivudine) plus either an Non-Nucleoside Reverse Tran-
scriptase Inhibitor (NNRTI) (usually efavirenz) or a protease
inhibitor (PI) with ritonavir are the most common initial
therapies.15 Raltegravir, an integrase inhibitor, maraviroc, a
CCR5 coreceptor inhibitor inhibiting HIV entry, and etra-
virine, a second generation NNRTI, and the fusion inhibitor
enfuvirtide have potent antiretroviral inhibition provided they
are associated with at least one and at best two fully active
agents and are usually prescribed in drug-experienced HIV-
infected subjects.
When managing NSCLC in HIV-infected subjects, PIs
with or without ritonavir may modify concentrations of an-
tineoplastic compounds through CYP450 inhibition, poten-
tially intensifying cytotoxic therapy adverse events.16 Some
antiretroviral compounds, such as zidovudine (ZDV), could
also be responsible for additive hematological toxicities with
antineoplastic drugs. Studies providing a detailed analysis of
factors involved in survival and adverse events with a com-
bination of HAART and cytotoxic chemotherapy are scarce
in HIV-infected subjects. Case reports and case series of
potentially lethal interactions between PI and chemotherapy
in Hodgkin lymphomas,16–19 Castelmann disease,20 or non-
Hodgkin lymphoma21,22 have been published, but data, par-
ticularly concerning non-AIDS defining cancers, including
NSCLC, are lacking.
The objective of our study was to describe factors
associated with increased survival rates in HIV-infected
subjects with NSCLC in a French cohort, the Dat’Aids
cohort.23 A substudy analyzed the occurrence of toxicities
induced by cytotoxic chemotherapy (the toxicity substudy)
and their association with specific antiretroviral classes
and compounds.
PATIENTS AND METHODS
Collection of Patient Data
Patients were included in the study if they were HIV
infected, followed in the Dat’Aids cohort and had a histolog-
ical diagnosis of NSCLC. The database was frozen on No-
vember 30, 2009. To allow a sufficient follow-up, we in-
cluded only patients with a diagnosis of NSCLC before
November 30, 2008. All the patients who were treated with
1 chemotherapeutic administration were included in a tox-
icity substudy. Administration of HAART with chemother-
apy was not mandatory for inclusion in the study.
Dat’Aids is a cohort derived from NADIS, an elec-
tronic medical record for HIV-infected patients seeking care
in French public hospitals. Patients’ data are recorded with no
time delay in a structured database, allowing use for clinical,
epidemiological, or therapeutic studies.23 Between January
1996 and November 30, 2009, 20,874 subjects had their data
recorded at least once in the base. All patients are included in
the NADIS medical record after receiving oral information
and giving written consent. The collected data and details of
the networking organization have been submitted to the
French National Commission on Informatics and rights. All
patients’ medical records included in the study were retro-
spectively reviewed by two of the authors (A.M. and J.-C.T.)
in each center and unit implicated in the caring of patients.
Statistical Analysis
The primary objective was to determine factors associ-
ated with survival after NSCLC diagnosis using Cox propor-
tional hazards models. Survival was defined by the absence of
death from any cause. Variables studied were gender, age,
CD4 level at NSCLC diagnosis, nadir CD4 level, a history
of AIDS according to the 1993 CDC classification, viral
load at diagnosis, diagnosis of adenocarcinoma or not,
performance status (PS) at NSCLC diagnosis, NSCLC
staging, and treatment with chemotherapy and antiretrovi-
ral therapy. NSCLC stages were reclassified according to
the proposals for the revision of the tumor, node, and
metastasis stage groupings in the forthcoming (seventh)
edition of the Tumor, Node, and Metastasis Classification
of Malignant Tumors of the IASLC Lung Cancer Staging
Project.24,25 Patients with stages I to II were pooled to-
gether, as were patients with stages IIIA and IIIB, to
increase statistical power. The multivariable Cox model
included all potential prognostic factors for survival with a
p value less than 0.2 in univariate analysis.
For the toxicity substudy, as patients could have
changed antiretroviral or cytotoxic therapy during their fol-
low-up, we defined a therapeutic combination as the specific
association of a defined HAART and chemotherapy type.
Modification of a therapeutic combination was defined as
either the changing of at least one of the cytotoxic compounds
(e.g., docetaxel to pemetrexed) or a switch of one of the
antiretroviral compounds from one antiretroviral class to
another (e.g., PI to integrase inhibitor) or the introduction or
interruption of ZDV in the backbone. The outcome variable
was the presence of grade 4 hematological toxicity according
to the Agence Nationale de Recherche sur le SIDA et les
hépatites virales (ANRS) clinical trial adverse event classifi-
cation, defined as a grade 4 neutropenia (500 cells/mm3), a
grade 4 anemia (hemoglobin level 6.5 g/dl), or a grade 4
thrombocytopenia (20,000 platelets/mm3). Marginal logis-
tic regression models, which account for correlation between
observations, were used to identify factors associated with
grade 4 hematological toxicity. The correlation of observa-
tions within each patient was modeled assuming exchange-
able correlation for the working correlation matrix, and the
variance was estimated by the sandwich estimator. In
addition to all the variables listed for survival analysis,
uses of PI or ZDV in HAART and first versus two or more
chemotherapy lines were also studied. Variables with a p
value less than 0.2 in the univariate approach were in-
cluded in the multivariable model.
All analyses were performed using Stata 10.1 (Stata
Corp, College Station, TX), and statistical significance was
set at 0.05.
RESULTS
Screening of the Dat’Aids database identified 52 sub-
jects that met inclusion criteria between 1996 and 2008. Of
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these, 42 were treated with cytotoxic chemotherapy, but two
subjects were excluded from the toxicity substudy as chemo-
therapeutic tolerance data were not available.
Baseline Characteristics and Patient
Description
Of the 52 included subjects in the study, 42 were men
(81%), median age at NSCLC diagnosis was 48 years, 98%
had been or were active smokers (median of 30 pack years),
median CD4 was 300 cells/l, and 38 (73%) had a CD4 cells
200/L at NSCLC diagnosis (Table 1). Median follow-up
time was 12 months (range: 0.6–83 months), and median
survival was 12 months.
Forty subjects were included in the toxicity substudy.
Characteristics were comparable with the main study, except
for the number of subjects with a nadir level of CD4 200
cells/l (Table 1). Patients received from one to five thera-
peutic combinations and overall 68 therapeutic combinations
were administered: 24 with docetaxel, 16 with gemcitabine,
and 12 with vinorelbine. The remaining combinations con-
tained pemetrexed (n  2), etoposide (n  2), erlotinib (n 
5), and gefitinib (n  2). Forty-five combinations were
platin-based doublets, and two had platinium-based triplets.
One subject received cisplatin monotherapy. Fourteen com-
binations included ZDV, 21 were NNRTI based, and 20 were
PI based (seven were ritonavir boosted, four also included a
NNRTI, and one raltegravir). Other HAART included ralte-
gravir  NRTI (n  4) and 3 NRTIs (n  8). Fifteen
combinations did not include any antiretroviral therapy.
Factors Associated with Survival
Results of the Cox models assessing factors associated
with survival in the 52 HIV-infected subjects with NSCLC
are listed in Table 2. Variables included in the multivariable
model were a CD4 level 200 cells/l at NSCLC diagnosis,
a PS less than 2, NSCLC stages, use of chemotherapy, and
use of HAART after lung cancer diagnosis. The characteris-
tics significantly associated with increased survival in the
multivariable model were CD4 levels 200 cells/l at
NSCLC diagnosis (hazard ratio [HR]  0.29, 95% confi-
dence interval [CI] [0.10–0.89]), a PS less than 2 (HR 
0.32, 95% CI [0.15–0.68]), and use of HAART after NSCLC
diagnosis (HR  0.26, 95% CI [0.09–0.74]). There was a
trend to an increased survival with use of cytotoxic chemo-
therapy in the unadjusted Cox model, but this element was no
longer statistically associated with increased survival (HR:
0.95, 95% CI [0.34–3.31]) after adjustment for other prog-
nostic factors. Stages I to II or III versus stage IV at lung
cancer diagnosis was not significantly associated with overall
survival in multivariate analysis, although there was a ten-
dency for stages I to II versus IV (HR  0.24, 95% CI
[0.05–1.20], p  0.08). Figure 1 assembles Kaplan-Meier
survival estimates according to HAART pursuit after NSCLC
diagnosis, CD4 level at NSCLC diagnosis, and PS.
Factors Associated with Grade 4 Toxicity
Overall, 14 of 68 therapeutic combinations were com-
plicated by a grade 4 hematological toxicity in 13 patients.
Characteristics and outcomes of the 14 combinations induc-
ing grade 4 hematological toxicity are summarized in Table
3. Nine of these combinations included a CYP-metabolized
agents (docetaxel n  3, vinorelbine n  5, and etoposide
n  1), of which seven had a PI coadministered. In contrast,
only one induced grade 4 hematological toxicity occurred in
a combination with an NNRTI. Among the 13 combinations
including ZDV, five combinations induced grade 4 toxicity.
Ten combinations resulted in grade 4 neutropenia, and all six
TABLE 1. Characteristics of Subjects Included in the Main
Study (Survival Study) and the Subanalysis (Analysis on
Chemotherapeutic-Induced Toxicities in HIV-Infected
Subjects with NSCLC)
Characteristics Total
Toxicity
Substudy
Total 52 40
Male sex, n (%) 42 (81) 31 (78)
Follow-up time (mo), median (range) 11.9 (0.6–82.7) 13.3 (0.6–82.7)
Median survival (mo), median 12.0 16.3
Death outcome, n (%) 37 (71) 28 (70)
Age (yr), median (range) 48 (32–77) 50 (32–77)
Smoker, n (%) 51 (98) 39 (98)
Median pack years, median (range)a 30 (10–90) 30 (10–90)
HCV coinfection, n (%) 18 (35) 13 (33)
PS 2 at NSCLC diagnosis, n (%) 34 (65) 29 (72)
Chemotherapy, n (%) 42 (81) 40 (100)
Chemotherapy line, n (%)
1 — 26 (65)
2 — 8 (20)
3 — 6 (15)
Adjuvant or neoadjuvant
chemotherapy
— 6 (15)
Antiretroviral therapy, n (%) 47 (90) 36 (90)
PI-based antiretroviral therapy, n (%) 26 (50) 18 (45)
Antiretroviral therapy during
chemotherapy, n (%)
— 33 (83)
Number of therapeutic combinations,
median (range)
— 1 (1–5)
CD4 count at NSCLC diagnosis,
median (range)
300 (25–1551) 365 (37–1551)
CD4 count 200 cells/l at
NSCLC diagnosis, n (%)
38 (73) 35 (87)
Nadir CD4 200 cells/l, n (%) 13 (25) 12 (30)
Viral load 200 copies/ml at
NSCLC diagnosis, n (%)
29 (56) 24 (60)
AIDS status, n (%) 16 (31) 7 (18)
NSCLC histological type, n (%)
Adenocarcinoma 37 (71) 26 (65)
Squamous carcinoma 14 (27) 14 (35)
Otherb 1 (2) 0
Staging, n (%)
Stages I/IIA/IIB 2/1/1 n  5 (10) 1/1/1 n  3 (8)
Stages IIIA/IIIB 6/7 n  13 (25) 5/6 n  11 (27)
Stage IV 34 (65) 26 (65)
a Precise evaluation of pack years were recorded for 41 subjects in the survival
study and 32 subjects in the toxicity substudy.
b Other denotes bronchioloalveolar adenocarcinoma.
HCV, hepatitis C-virus; PS, performance status; PI, protease inhibitor; NSCLC,
non-small cell lung cancer; AIDS, acquired immunodeficiency syndrome.
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deaths due to hematological toxicity were secondary to septic
shock occurring during a grade 4 neutropenia. Five of these
six deaths occurred under combinations with a PI, of which
four also included a CYP-metabolized cytotoxic compound.
Variables associated with grade 4 hematological toxic-
ity using marginal logistic regression models are listed in
Table 4. In the multivariable model, use of PI (odds ratio
[OR]  5.22, 95% CI [1.07–25.38]) was the only variable
significantly associated with a grade 4 hematological toxicity.
There was a trend to an increased risk of toxicity with the use
of ZDV (OR  4.24, 95% CI [0.75–23.90], p  0.10).
DISCUSSION
This study included subjects from a French National
Database of HIV-infected patients (the Dat’Aids cohort) with
NSCLC. We found that a PS less than 2, a CD4 count 200
cells/l at NSCLC diagnosis, and use of HAART after
NSCLC diagnosis were significantly associated with in-
creased survival in the multivariable model. We also found
that the use of a PI-containing antiretroviral regimen with
cytotoxic chemotherapy was independently associated with at
least one episode of hematological grade 4 toxicity. Death
due to hematological toxicity was mostly observed in patients
receiving a PI.
In comparison with NSCLC in the general population,
NSCLC in HIV-infected patients is characterized by young
age at diagnosis and an increased proportion of advanced
stages III and IV at diagnosis.26–28 Nearly all HIV-infected
subjects with NSCLC are smokers. Histological subtypes in
the HIV-infected population follow the patterns of histological
subtypes in the general population, with a predominance of
adenocarcinoma (31–52%) followed by carcinoid epidermoid
(17–50%) and other histological subtypes.5,27–29 The subjects
included in our study compared well with the retrospective
studies of NSCLC of the HIV-infected population in regards to
the patients’ baseline characteristics, advanced stages of discov-
ery, and dismal prognosis: median age was 48 years, 71% had
adenocarcinoma, 27% squamous carcinoma, nearly all were
smokers, 90% had their NSCLC discovered at advanced stages
III or IV, and median survival was 12 months.
The factors associated with increased survival in our
study are similar to those of a recent retrospective study of 49
HIV-infected subjects with NSCLC.26 Lavole et al. also
found that PS less than 2 and treatment with HAART were
associated with improved survival in multivariate analyses
(respectively, HR  0.2, 95% CI [0.09–0.46] and HR  0.4,
95% CI [0.2–0.9]). PS is a well-known prognostic factor in
NSCLC and cancers in the general population30 and has been
highlighted as an essential prognostic factor in some cancers
in the HIV-infected population.31 We confirm the importance
of PS as a significant survival prognostic factor in NSCLC in
the HIV-infected population in our study, as well as the use
of HAART, underscoring the necessity of initiating or pur-
suing HAART after NSCLC diagnosis whenever possible.
Whether increased survival with HAART reflects immune-
mediated control of the tumor needs to be further investi-
gated, but survival seemed to be independent of opportunistic
infections in our study, as they did not occur. Other studies
have also confirmed enhanced survival and remission rates
with a strategy of pursuing HAART with chemotherapy for
non-Hodgkin22,32–36 and Hodgkin lymphomas.37,38
We found that the level of CD4 200 cells/l at
NSCLC diagnosis was associated with increased survival.
Several studies have highlighted the role of HIV-induced
immunodeficiency in the occurrence of lung cancer.8,9
Guiguet et al. found in 52,278 patients followed up in the
French Hospital Database on HIV cohort during 1998–2006
that the current CD4 cell count was the most predictive risk
factor for lung cancer. Compared with patients with CD4
count greater than 500 cells/l rate, ratios ranged from 2.2
(1.3–3.6) to 8.5 (4.3–16.7) for lung cancer for CD4 levels of
350–499 cells/L and less than 50 cells/l, respectively (p
0.0001). The rapid evolution and the high proportions of
advanced stage lung cancers at diagnosis in the HIV-infected
TABLE 2. Factors Associated with Survival
Characteristics
Univariate Analyses Multivariate Analysis
Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Male sex 1.06 0.46–2.45 0.89
Age 48 yr 0.95 0.48–1.85 0.87
CD4 200 cells/l 0.47 0.22–0.98 0.044 0.29 0.10–0.89 0.027
Nadir CD4 200 cells/l 0.91 0.42–1.97 0.82
AIDS status 1.18 0.58–2.42 0.65
Viral load 200 copies/ml 0.71 0.37–1.36 0.30
Adenocarcinoma 0.77 0.38–1.55 0.46
PS 2 0.34 0.17–0.66 0.002 0.32 0.15–0.68 0.003
Stage
I–II 0.33 0.08–1.38 0.13 0.24 0.05–1.20 0.08
III 0.58 0.26–1.28 0.17 0.77 0.33–1.80 0.55
IV 1.00 — — 1.00 — —
HAART 0.28 0.10–0.74 0.011 0.26 0.09–0.74 0.012
Use of cytotoxic chemotherapy 0.55 0.25–1.22 0.14 0.95 0.34–3.31 0.92
PS, performance status; AIDS, acquired immunodeficiency syndrome; OR, odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy.
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population,5,27,28 as encountered in our study, also suggest an
increased tumor cell proliferation in HIV-infected patients
with NSCLC potentially fostered by cellular immunodefi-
ciency. A recent phase II clinical trial in the non-HIV-
infected patients with NSCLC showed some survival benefit
of cellular vaccination against tumoral cells, underscoring the
importance of immunity in controlling the disease.39 Similar
to our study, another retrospective study of 92 HIV-infected
patients with NSCLC showed, after adjustment on NSCLC
stage at diagnosis, that CD4 counts levels less than 400
cells/l and less than 200 cells/l were significantly associ-
ated with increased mortality (respectively, HR: 1.61; 95% CI
[0.82–3.16] and HR: 2.64; 95% CI [1.37–5.10]) in compari-
son with CD4 levels more than 400 cells/l.28
Our study did not find an independent association
between NSCLC stages and survival, a factor commonly
associated with increased survival in the general population
with NSCLC and in the HIV-infected population.26 Never-
theless, NSCLC stages I to II had a trend to increased survival
in comparison with subjects with stage IV (HR  0.24; 95%
CI [0.05–1.20], p  0.08). These results could be partially
explained by a lack of power in our study, as only five
subjects (10%) were classified as stage I or II and 13 (25%)
as stage III (A or B). Also, one patient staged IA and three
staged IIIA did not have surgery, and one patient with stage
IIIA NSCLC did not have neoadjuvant chemotherapy.
Use of cytotoxic chemotherapy was not associated with
overall survival. This result could be explained not only by
lack of power of our retrospective study but also because few
patients did not receive chemotherapy (Table 1). Some pa-
tients received chemotherapy (such as the well-tolerated gem-
citabine monotherapy) as palliative care, solely aimed to
relieve symptoms. In the general population with advanced
NSCLC, chemotherapy has only shown a moderate increase
in survival. A meta-analysis of 16 prospective randomized
trials comparing chemotherapy with best supportive care in
2714 subjects with advanced NSCLC showed only a very
modest increase in the 1-year survival of 20 to 29%.40
FIGURE 1. Kaplan-Meier survival estimates according to (A) HAART pursuit after NSCLC diagnosis, (B) PS, and (C) CD4 value
at NSCLC diagnosis. HAART, highly active antiretroviral therapy; PS, performance status; NSCLC, non-small cell lung cancer.
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Increased survival with newer agents targeting tyrosine ki-
nase pathways have shown enhanced survival of gefitinib
versus carboplatin-paclitaxel in adenocarcinoma, particularly
in East Asian and non or light smokers,13 and with erlotinib
in subjects with the activating mutations in the epidermal
growth factor genes.41 In our study, only seven combinations
included gefitinib or erlotinib in second or third-line thera-
pies, and none had epidermal growth factor receptor gene
mutation screening or any favorable factor associated with
increased survival in NSCLC.
In the toxicity substudy, use of PI was significantly
associated in multivariate analyses with more frequent grade
4 hematological toxicity. ZDV use was not significantly
associated with grade 4 toxicity, although there was a trend.
These results and the detailed description of the 14 combi-
nations that induced these grade 4 toxicities underscore two
possible mechanisms of toxicity: the first through CYP450-
mediated interactions between PI and CYP-metabolized cy-
totoxic compounds (primarily vinorelbine and docetaxel) and
the second through ZDV additive hematological depletion
enhanced by cytotoxic compounds. Antineoplastic agents
used in NSCLC and metabolized by the CYP450 include
taxanes, vinca alkaloids, etoposide, and the anilinoquinazo-
lines erlotinib and gefitinib.16,42–44 All PIs inhibit CYP450
3A4, but ritonavir is the most potent inhibitor in the class,
even at low doses.45,46 Ritonavir is also a potent inhibitor of
the P-glycoprotein efflux pump protein, driving chemothera-
peutic drugs, such as vinca alkaloids and taxanes, outside
tissues and cells.47,48 The frequent occurrence of grade 4
hematological toxicity early in the cycles of most CYP-450-
mediated chemotherapy and PI administration during the first
of chemotherapy lines line supports a toxicity mechanism
through drug to drug interaction (Table 3). Case reports of
life-threatening neutropenia possibly due to CYP-450-medi-
ated interactions have been published between PI inhibitors
and taxanes,49–51 or vinca alkaloids.16,22,52 In a recent analysis
of 16 HIV-infected subjects with Hodgkin lymphoma treated
by vinblastine-based chemotherapy, use of PI-containing
HAART was significantly associated with grades III to IV
World Health Organization neutropenia.19 ZDV hematologi-
cal toxicities, including anemia and neutropenia, are well-
known adverse events,53 and use of ZDV with chemotherapy
should be avoided.54 PS less than 2 was not associated with
increased grade 4 hematological toxicity in the multivariable
TABLE 3. Characteristics and Outcomes of the 13 HIV-Infected Subjects (14 Therapeutic Combinations) with Grade 4
Hematoxicity
Patient Cytotoxic Chemotherapy HAART
No. of Cycles
Before Toxicity
Chemotherapy
Line/No. of Lines Stage
Type of
Toxicity
Hematological
Deaths
1 Cisplatin  gemcitabine TDF/FTC/LPV/r 2 1/2 IV Neutropenia No
1 Docetaxel TDF/FTC/LPV/r 1 2/2 Neutropenia No
2 Docetaxel LPV/r/NVP 1 2/2 IIIB Neutropenia Yes
3 Cisplatin  etoposide IDV/ZDV/3TC 3 1/1 IV Neutropenia No
4 Cisplatin  vinorelbine ZDV/3TC/EFV 2 1/1 IIIB Anemia No
5 Cisplatin  vinorelbine ZDV/3TC/SQV/r 1 1/1 IV Neutropenia Yes
6 Cisplatin  gemcitabine None 2 1/1 IV Neutropenia Yes
7 Cisplatin  gemcitabine ZDV/3TC/ABC/DDI 1 1/4 IV Neutropenia No
8 Cisplatin  vinorelbine LPV/r/ZDV/3TC/ABC 1 1/1 IV Neutropenia Yes
9 Carboplatin  gemcitabine 
bevacizumab
None 2 1/1 IV Thrombopenia No
10 Cisplatin  gemcitabine LPV/r/D4T/3TC 3 1/1 IV Neutropenia Yes
11 Cisplatin  vinorelbine None 2 1/1 IV Anemia No
12 Docetaxel FPV/r/ABC/3TC 1 1/1 IV Neutropenia Yes
13 Cisplatin  vinorelbine SQV/3TC/D4T 1 1/2 IV Anemia No
Patient 2 had first-line chemotherapy with gemcitabine and cisplatin.
TDF, tenofovir; FTC, emtricatine; LPV/r, lopinavir  ritonavir; NVP, nevirapine; IDV, indinavir; ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; DDI, didanosine; D4T,
stavudine; FPV, fosamprenavir; SQV, saquinavir; EFV, efavirenz; HAART, highly active antiretroviral therapy.
TABLE 4. Factors Associated with Grade 4 Hematoxicity in
the Toxicity Substudy
Characteristics
Unadjusted
Analyses
Adjusted
Analysis
OR 95% CI p OR 95% CI p
Male sex 2.53 0.47–13.74 0.28
Age 48 yr 0.61 0.17–2.25 0.46
CD4 200 0.52 0.07–3.67 0.51
Nadir CD4 200 0.99 0.24–4.11 0.99
AIDS status 0.72 0.13–3.92 0.71
Viral load 200
copies/ml
1.12 0.29–4.30 0.87
Adenocarcinoma 0.71 0.18–2.74 0.62
PS 2 0.26 0.06–1.09 0.066 0.41 0.07–2.56 0.34
Stage I/II/III vs. IV 0.23 0.04–1.19 0.080 0.32 0.05–2.15 0.24
First line versus
 second-line
chemotherapy
3.14 0.76–12.97 0.11 3.00 0.44–20.59 0.26
Use of PI 6.62 1.76–24.96 0.0052 5.22 1.07–25.38 0.041
Use of ZDV 3.61 0.87–15.05 0.078 4.24 0.75–23.90 0.10
AIDS, acquired immunodeficiency syndrome; PS, performance status; PI, protease
inhibitor; ZDV, zidovudine; OR, odds ratio; CI, confidence interval.
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model (OR  0.41, 95% CI [0.07–2.56]) (Table 4). This
result could be explained by a lack of power in our study, as
PS is a well-known prognostic factor of cytotoxic chemother-
apy tolerance in lung cancer in the general population.55
Our study has some methodological shortcomings.
First, although the Dat’Aids cohort is a prospective cohort,
some data had to be completed retrospectively, particularly
those concerning chemotherapies and adverse events. Never-
theless, we believe that the careful study of each patient’s
medical record resulted in reliable information. Second, our
study results were limited by the number of subjects included.
We could not analyze, for instance, a potential difference in
terms of toxicity of a ritonavir boosted or nonboosted PI-
containing regimens. Nevertheless, although lung cancer is in
most cohorts the first non-AIDS defining cancer in HIV-
infected subjects,1,3–7 incidence rates are relatively low, mak-
ing studies with an important number of subjects difficult to
carry out.
In conclusion, our study showed that PS less than 2,
HAART during chemotherapy, and a CD4 level 200
cells/l at NSCLC diagnosis were associated with increased
survival in a HIV-infected population with NSCLC, mostly
with advanced NSCLC stages. Subjects with NSCLC stages
I to II had a better outcome than subjects with stage IV
NSCLC, although this difference was not statistically signif-
icant. These results advocate the use of HAART during
chemotherapy for NSCLC, and the early implementation of
HAART, as severe immunological depression could enhance
the risk of NSCLC and nonresponse to antineoplastic chemo-
therapy. Our study also underscores the importance of install-
ing smoking interruption programs in the HIV-infected pop-
ulation as nearly all HIV-infected subjects with lung cancers
are smokers. Our toxicity substudy also suggests that use of
non-PI-based HAART may be preferred when cytotoxic che-
motherapies metabolized by the CYP450 pathway are admin-
istered. The choice of chemotherapy and HAART in HIV-
infected patients with NSCLC should be individualized and
multidisciplinary and decided in light of the possible inter-
actions and additive toxicities between compounds, while
preserving quality of life and viral suppression. Clinical and
PK studies of interactions with chemotherapy and antiretro-
viral drugs are warranted for NSCLC and other cancers in the
HIV-infected population, as well as prospective data on
survival.
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